Cure8 research brief
Low zinc levels were linked with higher one-year relapse risk in UC patients in remission; knowing zinc status might add prognostic information beyond standard labs.
Adults with ulcerative colitis in remission, gastroenterologists and IBD clinicians, researchers studying nutritional biomarkers and relapse prediction.
This study measured baseline serum zinc in 102 patients with ulcerative colitis (UC) who were in clinical remission and followed them for one year.
Patients with hypozincemia (<80 μg/dL) had a higher rate of clinical relapse and shorter relapse-free survival than patients with normal zinc; in multivariable analysis, having normal zinc was associated with reduced relapse risk independent of CRP, albumin, and prior biologic use.
What this means for patients The paper suggests serum zinc measured while in remission may help identify people at higher short-term relapse risk. This is an observational single-center study, so it shows an association rather than proving that zinc deficiency causes relapse or that treating it will prevent relapse.
Practical notes If zinc status is a concern, discuss testing with your clinician; the study used a threshold of 80 μg/dL. Decisions about supplementation or management should be individualized and guided by a clinician—this study does not provide treatment recommendations.
This is a single-center observational study (abstract-level content provided). It shows an association, not causation, and does not report effects of treating hypozincemia. Clinical decisions should rely on broader evidence and individual patient context.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Non-invasive urine biomarkers could make diagnosis and disease-activity monitoring easier and less invasive for people with IBD. Identifying metabolites linked to UC activity may help tailor monitoring without frequent...
A blood biomarker that rises with active ulcerative colitis could help patients and clinicians monitor disease activity without relying solely on invasive tests. This study reports that serum type 23 collagen ectodomain...
Non-invasive biomarkers that reflect mucosal inflammation and systemic disease activity could help reduce reliance on frequent endoscopy and guide monitoring for people with Crohn’s disease or ulcerative colitis.
